Distal Convoluted Tubule

Arohan R. Subramanya*†‡ and David H. Ellison§¶

Abstract
The distal convoluted tubule is the nephron segment that lies immediately downstream of the macula densa. Although short in length, the distal convoluted tubule plays a critical role in sodium, potassium, and divalent cation homeostasis. Recent genetic and physiologic studies have greatly expanded our understanding of how the distal convoluted tubule regulates these processes at the molecular level. This article provides an update on the distal convoluted tubule, highlighting concepts and pathophysiology relevant to clinical practice.


Introduction
The distal convoluted tubule (DCT) is the portion of the nephron that is immediately downstream of the macula densa. Although the DCT is the shortest segment of the nephron, spanning only about 5 mm in length in humans (1), it plays a critical role in a variety of homeostatic processes, including sodium chloride reabsorption, potassium secretion, and calcium and magnesium handling. The DCT has a unique capacity to adapt to changes in hormonal stimuli and the contents of the tubular lumen, and this process contributes to the pathophysiologic basis of a number of clinically relevant scenarios, including loop diuretic resistance and hyperaldosteronism. In recent years, insights gained from Mendelian disorders of BF and electrolyte imbalance, genetically modified animal models, and molecular cloning and study of key components of the machinery that controls the diverse ion transport processes housed in this segment have greatly expanded our understanding of distal tubule function. In this article, we provide a focused overview and update of the molecular physiology of the DCT.

Distal Nephron Nomenclature and Anatomic Considerations
The term distal tubule has been used by anatomists to denote the region of the nephron that extends downstream from the macula densa to the confluence of another tubule (i.e., the collecting system) (Figure 1) (2). It includes two nephron segments, the DCT and the connecting tubule (CNT). The DCT can be further divided into two functionally distinct subsegments, referred to as the DCT1 and the DCT2 (also called the early and late DCTs).

The DCT1 and DCT2 can be distinguished by their differential responsiveness to the mineralocorticoid aldosterone. Aldosterone is a steroid hormone that is released from the adrenal gland in response to volume depletion or hyperkalemia. It has a similar chemical structure to glucocorticoids, such as cortisol, and both aldosterone and cortisol bind to the mineralocorticoid receptor with nearly equal affinity (3). Although mineralocorticoid receptors are expressed throughout the entire DCT, the DCT2 is sensitive to the actions of aldosterone, because it expresses an enzyme called 11-β hydroxysteroid dehydrogenase 2 (11-βHSD2). 11-βHSD2 metabolizes cortisol to the inactive metabolite cortisone, thereby preventing circulating glucocorticoids from binding to mineralocorticoid receptors expressed in the DCT2 (4). Because the mineralocorticoid receptors in the DCT2 can only be occupied by aldosterone, the DCT2 is more sensitive than the DCT1 to changes in circulating aldosterone levels. 11-βHSD2 is also expressed in other downstream nephron segments, including the CNT and the cortical collecting duct (CCD). For this reason, the DCT2, CNT, and CCD are collectively termed the aldosterone-sensitive distal nephron (5).

Cells of the DCT have a unique morphology that matches their highly active physiology (Figure 1, insets) (6). Their nuclei tend to be positioned to the apical side of the cell because of an extensive basolateral membrane that has numerous deep infoldings. In addition, the cytosol on the basal aspect of DCT cells is packed with mitochondria—in fact, cells of the DCT are among the most mitochondria-rich in the kidney (7). These findings indicate that the DCT engages in processes that require considerable ATP consumption and active transport of electrolytes driven by the basolateral Na⁺-K⁺-ATPase.

Mechanism of Na⁺ Reabsorption in the DCT
Apical Sodium Transport in the Early and Late DCTs
The DCT reabsorbs roughly 5%–10% of the filtered sodium load (8). The thiazide-sensitive NaCl cotransporter (NCC; TSC; SLC12A3) is chiefly responsible for this process. NCC is one of the major targets of thiazide-type diuretics; the other target is sodium-dependent chloride bicarbonate exchanger (NDCBE; SLC4A8), a
recently discovered Na\(^{+}\)-driven chloride bicarbonate exchanger expressed in the CCD (9). This class of drugs is commonly used to treat hypertension, edema, and nephrolithiasis and include the thiazides chlorothiazide, hydrochlorothiazide, and bendroflumethiazide (only available combined with nadolol in the United States) as well as the thiazide-like diuretics metolazone, indapamide, and chlorothalidone. As shown in Figure 2, in the DCT1, sodium absorption from the tubular lumen is chloride-dependent and entirely mediated by NCC (10). Because a negatively charged chloride anion enters in 1:1 stoichiometry with a sodium cation, this process is electrically silent or electro-neutral. Loss-of-function mutations of NCC cause Gitelman syndrome, an autosomal recessive salt wasting disorder that commonly presents with low-to-normal BP, elevated renin levels, hypokalemia, metabolic alkalosis, hypocalciuria, and hypomagnesemia (11). Thus, the phenotype of Gitelman syndrome is similar to the effects of thiazide diuretics. Most Gitelman mutations introduce changes into the NCC polypeptide that cause the cotransporter to misfold (12). This results in enhanced recognition by a molecular chaperone protein called Hsp70, which binds to misfolded NCC as it is being made in the endoplasmic reticulum and targets it for degradation (13,14).

NCC is expressed throughout the DCT, but the DCT2 also exhibits an amiloride-sensitive sodium transport pathway mediated by the epithelial sodium channel (ENaC) (Figure 2) (15,16). ENaC-mediated sodium transport is electrogenic; thus, in the DCT2, movement of Na\(^{+}\) ions through ENaC without an accompanying anion leaves negative charges in the lumen. Therefore, the transepithelial voltage or sum of membrane potentials on the luminal and basolateral membranes of the DCT epithelium is lumen-negative. As will be discussed below, this electrical gradient provides a driving force for the movement of other ions. Because ENaC is also expressed in the CNT and collecting duct, the transepithelial voltage becomes progressively more lumen-negative downstream of the DCT (17,18).

### Basolateral Sodium Transport

In both subsegments of the DCT, after the transapical movement of Na\(^{+}\) through NCC and/or ENaC, Na\(^{+}\) is extruded from the cytosol and into the peritubular fluid by the Na\(^{+}\)-K\(^{+}\)-ATPase (Figure 2). Because this electrogenic pump exchanges sodium for potassium at a stoichiometry of 3:2, its activity removes one positive charge from the intracellular space, resulting in the generation of a constant negative voltage of \(-60\) to \(-90\) mV across the basolateral membrane (19,20). Along the basolateral membrane, the intracellular voltage becomes more negative with respect to extracellular voltage if the intracellular sodium concentration increases. This finding suggests that, in the DCT, a rise in luminal NCC- or ENaC-mediated sodium transport stimulates basolateral Na\(^{+}\) extrusion through the Na\(^{+}\)-K\(^{+}\)-ATPase (19).
cles K role in this process (21). By transporting K by others. The Gitelman-like phenotype seen in individuals with the syndrome is likely caused by impaired K+ transport is reduced in these patients (Figure 3). To date, EAST/SeSAME syndrome is the only clinical distal tubular disorder known to affect a basolateral potassium channel. However, Kir4.1 is not the only potassium channel expressed at the basolateral membrane of the DCT. In fact, a number of K+ channels are expressed basolaterally, including Kir4.2 (KCNJ15) and Kir5.1 (KCNJ16) (21). Kir4.1 may associate in complexes with these alternative K+ transport pathways to form heteromultimers that cooperate in basolateral K+ recycling (27).

**Figure 2. | A model of NaCl reabsorption by cells of the early and late DCTs.** Note that the transepithelial voltage is close to zero in the DCT1 and becomes progressively negative in the DCT2. In the early DCT, apical sodium reabsorption is exclusively mediated by thiazide-sensitive NaCl cotransporter (NCC), whereas in the late DCT, both NCC and amiloride-sensitive epithelial sodium channels (ENaCs) are present. The electrogenic transport of sodium by ENaC contributes to the lumen-negative transepithelial voltage. Basolateral sodium efflux is mediated by the Na+-K+-ATPase and aided by Kir4.1-mediated potassium leak currents. Chloride transport is carried out by the chloride channel ClC-Kb and potassium chloride cotransporter 4 (KCC4; SLC12A7).

provides an effective mechanism by which sodium ions can be transported transcellularly (i.e., through cells) and returned back to the plasma.

**Basolateral K+ Channels**

In order for sodium to be reabsorbed through transcellular mechanisms, basolateral sodium transport through the Na+-K+-ATPase must match the rate of apical sodium flux. Basolateral K+ efflux pathways play an important role in this process (21). By transporting K+ extracellularly, basolateral potassium channels create a “leak” that recycles K+ and helps to maintain the activity of the sodium pump (Figure 2). This so-called “pump leak coupling” maximizes the sodium reabsorptive capacity of an epithelium (22). Although renal physiologists have long appreciated this concept (23), its medical relevance only recently came to light through studies of a rare genetic disorder called EAST/SeSAME (24,25). In 2008, two groups reported that patients with mutations in the DCT-expressed basolateral inward-rectifying K+ channel Kir4.1 (KCNJ10) develop a hereditary salt wasting hypokalemic and hypomagnesemic disorder resembling Gitelman syndrome (24,25). Patients with these mutations typically present in infancy with a constellation of neurologic abnormalities in addition to the renal salt loss; for this reason, the disease has been named EAST syndrome (epilepsy, ataxia, sensorineural deafness, and tubulopathy) by some investigators and SeSAME syndrome (seizures, sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance) by others. The Gitelman-like phenotype seen in individuals with the syndrome is likely caused by impaired K+ transport is reduced in these patients (Figure 3). To date, EAST/SeSAME syndrome is the only clinical distal tubular disorder known to affect a basolateral potassium channel. However, Kir4.1 is not the only potassium channel expressed at the basolateral membrane of the DCT. In fact, a number of K+ channels are expressed basolaterally, including Kir4.2 (KCNJ15) and Kir5.1 (KCNJ16) (21). Kir4.1 may associate in complexes with these alternative K+ transport pathways to form heteromultimers that cooperate in basolateral K+ recycling (27).

**CL− Absorption in the DCT**

**Apical Chloride Transport Pathways**

In the early DCT, chloride is transported transcellularly from the tubular lumen with sodium through NCC. Sodium and chloride transport through this cotransporter is interdependent; thus, inhibition of NCC by thiazide diuretics will effectively block chloride reabsorption in the earliest loops of the distal nephron. As mentioned above, on reaching the late DCT, sodium is also transported through amiloride-sensitive ENaCs, which generate a lumen-negative transepithelial potential. This, in turn, serves as a driving force for chloride transport into the peritubular space through paracellular mechanisms (Figure 2). Paracellular transport (i.e., the transport of ions between cells) is a passive process, but cells generally confer specificity to the process by expressing multiprotein complexes at or near the tight junctions that connect adjacent cells. Included among these complexes is a large family of molecules called claudins (28). Current data indicate that different regions of the nephron express specific combinations of claudin proteins, which help to define the paracellular ion selectivities of those nephron segments.

**Basolateral Chloride Transport**

Because sodium transport in the DCT largely occurs through the coupled transcellular transport of sodium and chloride, basolateral Cl− transport is essential to the development of a gradient for Na+ entry. Cl− exit also helps to lower the intracellular Cl− concentration, which is a potent activator of NCC, and maintains net Na+ reabsorption (29). Cl− exit across the human DCT basolateral membrane is mediated by the chloride channel CIC-Kb. The Na+-K+-ATPase is necessary for this process, because it generates an electrochemical gradient that favors chloride efflux. CIC-Kb channels require an accessory subunit called Barttin to be fully
Both the ClC-Kb channel and Barttin are also expressed in the thick ascending limb. Thus, it is perhaps not surprising that loss-of-function mutations of either gene cause specific subtypes of Bartter syndrome (30,31). Patients with ClC-Kb channel mutations tend to present with a mixed Bartter/Gitelman phenotype, whereas patients lacking functional Barttin present with a severe neonatal salt wasting disorder that includes sensorineural deafness.

The potassium chloride cotransporter 4 (KCC4; SLC12A7) is expressed in the basolateral membrane of the DCT and mediates coupled electroneutral K-Cl efflux (32). KCC4 activity is stimulated by hypotonicity (33). Because luminal fluid in the DCT is hypotonic relative to plasma (34), the extracellular environment of the DCT theoretically favors KCC activation. This finding is particularly relevant in the DCT2, where tubular fluid is diluted down to 100 mOsM. Thus, a significant fraction of basolateral chloride reabsorption in the late DCT probably occurs through this transport pathway. Although no clinical syndrome involving KCC4 mutations has been described, KCC4 knockout mice develop renal tubular acidosis and deafness (35). This suggests that KCC4 plays an important role in determining renal net acid excretion and K^+ secretion into the endolymph of the inner ear, although the mechanisms mediating such processes remain poorly defined.

Regulation of NaCl Transport in the DCT

Although sodium transport in the DCT is mediated by both NCC and ENaC, in this section, we will predominantly focus on the regulation of NCC-mediated Na^+ transport. A detailed review of ENaC regulation is covered elsewhere in this series.
Distal Na\textsuperscript{+} Delivery

NaCl reabsorption in the DCT is dependent on sodium delivery. As the delivered sodium load is increased, the DCT responds by increasing its capacity for sodium transport. These changes are associated with marked alterations in DCT cell morphology, including an increase in basolateral membrane surface area and increased mitochondrial size (36). In concordance with these hypertrophic changes, Na\textsuperscript{+} – K\textsuperscript{+} – ATPase activity and the number of NCC cotransporters expressed per cell both increase dramatically. Thus, luminal sodium seems to be a potent stimulus that induces hypertrophy and activity of the distal tubule. The cellular mechanisms whereby NaCl entry affects NCC transport function and DCT morphology are not known.

The most common clinical scenario in which this phenomenon is encountered is loop diuretic resistance (Figure 4) (37). Chronic treatment with diuretics that inhibit the Na-K-2Cl cotransporter in the loop of Henle (bumetanide-sensitive sodium-potassium-chloride cotransporter [NKCC2, SLC12A1]), such as furosemide, results in a sustained increase in luminal Na\textsuperscript{+} delivery to the DCT. This induces hypertrophic changes in the DCT that increase NCC-mediated NaCl reabsorption, diminishing the effects of loop diuretics over time (36). Because of these hypertrophic changes, edematous patients who are loop diuretic-resistant and do not have severe CKD will frequently be highly sensitive to the effects of thiazide diuretics. Thus, the addition of even low doses of a thiazide or thiazide-like diuretic often results in a dramatic increase in urinary salt and water excretion.

The WNK-SPAK/OSR1 Signaling Pathway and NCC

For thiazide-sensitive sodium chloride reabsorption to occur in the DCT, two processes must take place. First, a sufficient number of NCC cotransporters must be present at the DCT apical membrane, where they can come into contact with salt in the tubular lumen and facilitate NaCl cotransport. To get to the apical membrane, NCC must traffic there from a storage pool of vesicles present inside DCT cells (Figure 5). Second, cotransporters present at the DCT lumen must be switched on by phosphorylation. Two related serine threonine kinases, the Ste20-like proline-alanine rich kinase (SPAK) and oxidative stress responsive kinase 1 (OSR1), phosphorylate NCC directly (38). Both of these proteins transfer phosphate groups from ATP to serine and threonine residues present in the intracellular NCC amino terminus (Figure 5). By doing so, SPAK and OSR1 enhance the ability of the cotransporter to transport sodium and chloride, presumably by altering its protein conformation.

A family of proteins called With-None-Lysine [amino acid=K] kinases (WNKs) phosphorylates and activates SPAK and OSR1. They can also regulate NCC trafficking by separate mechanisms. These serine threonine kinases were identified as NCC regulators slightly over a decade ago through studies of a rare inherited disorder called Familial Hyperkalemic Hypertension (FHH; also known as pseudohypoaldosteronism type 2 or Gordon syndrome) (39). FHH\textsubscript{t} is characterized by the unusual triad of hypertension, hyperkalemia, and normal GFR. Other features include metabolic acidosis and hypercalciuria. Thus, patients with FHH\textsubscript{t} have a phenotype that is essentially the mirror image of Gitelman syndrome. Moreover, FHH\textsubscript{t} is exquisitely sensitive to thiazide diuretics, indicating that the disorder is primarily a syndrome of NCC overactivity (40). In 2001, mutations in two WNKs, WNK1 and WNK4, were identified as the cause of FHH\textsubscript{t} (41). Although mutations in WNKs were the first to be implicated in the pathogenesis of FHH\textsubscript{t}, they only account for a minority of families affected by the disorder. Most FHH\textsubscript{t}-affected individuals harbor mutations in two other genes: the E3 ubiquitin ligase Cullin 3 (CUL3) and its adaptor, Kelch-like-3 (KLHL3) (42,43). These two proteins participate in a protein complex that degrades WNK1 and WNK4. A very recent series of papers from several laboratories show that CUL3 covalently attaches ubiquitin molecules to WNK1 and WNK4, marking them for disposal (44–46). To do so, KLHL3 must be present, because it connects CUL3 to the WNKs (Figure 6A).

An elaborate interrelationship between WNK1, WNK4, and the KLHL3/CUL3 complex underlies the pathogenesis of FHH\textsubscript{t}. WNK1 and WNK4 regulate NCC through distinct mechanisms. According to current models, in the baseline state, where NCC is inactive and WNK4 kinase activity is switched off, WNK4 acts as an inhibitor, suppressing NCC trafficking to the cell surface (Figure 6A) (47–49). FHH\textsubscript{t}-causing WNK4 mutations are missense mutations that reduce WNK4 binding to KLHL3 (44,46). Total WNK4 protein expression, therefore, is increased in patients who have these mutations (Figure 6B). Disease-causing WNK4 mutants can phosphorylate SPAK and OSR1 (50), but many of them cannot block NCC plasma membrane trafficking (51,52). Thus, increased mutant WNK4 protein expression stimulates NCC phosphorylation and trafficking to the cell surface, resulting in NCC overactivation (Figure 6B) (44,46).

Like WNK4, the kinase active form of WNK1 phosphorylates and activates SPAK and OSR1 (53). In contrast to WNK4, however, WNK1 does not inhibit NCC trafficking. Rather, kinase-active WNK1 reverses the inhibitory effect of WNK4 on NCC traffic (Figure 6, A and C) (48,51). It likely mediates this reversal by binding to and phosphorylating WNK4 (54). Although these complexes cannot block NCC trafficking, they can still stimulate NCC phosphorylation. Thus, high levels of kinase-active WNK1 protein expression facilitate NCC trafficking to the cell surface and enhance NCC phosphorylation status through SPAK/OSR1. FHH\textsubscript{t}-causing mutations in WNK1 are intron deletions that do not alter the protein structure. Instead, these mutations increase total WNK1 mRNA and protein expression (41). The increased protein expression overrides ubiquitination and degradation by the KLHL3/CUL3 complex, and the net effect of the mutation is to increase total WNK1 kinase activity (55). Thus, in FHH\textsubscript{t} caused by mutations of WNK1, increased WNK1 protein expression should suppress the inhibitory effect of WNK4 on NCC traffic while stimulating SPAK and OSR1, causing NCC to be overactive (Figure 6C).

FHH\textsubscript{t}-associated mutations in KLHL3 reduce binding of the KLHL3/CUL3 complex to WNK1 and WNK4 (45) (Figure 6D). Thus, mutations in KLHL3 diminish the amount of CUL3-mediated WNK1 and WNK4 degradation (44–46). This increases WNK1 and WNK4 abundance, resulting in enhanced WNK-dependent signaling and NCC activation (Figure 6D). Mutations in CUL3 always cause...
Figure 4. Effect of chronic loop diuretic administration on DCT activity and morphology. (Upper panel) Sodium reabsorption normally mediated by the thick ascending limb Na-K-2Cl cotransporter (NKCC2) is blocked by loop diuretics, such as furosemide and bumetanide. This results in enhanced $\text{Na}^+$ delivery to the DCT, which likely acts as a stimulus for DCT hypertrophy. (Lower panel) DCT hypertrophy manifests as an increase in mitochondrial size and basolateral membrane infoldings. The increase in NCC-mediated apical sodium transport coupled with enhanced activity of the sodium/potassium pump at the basolateral membrane results in a vectorial increase in sodium reabsorption and diuretic resistance.
skipping of an exon, resulting in an in-frame deletion (42). It seems likely that this specific change in the CUL3 protein structure reduces WNK1 and WNK4 ubiquitination, but this remains to be tested.

Several clinically relevant hormones stimulate salt reabsorption in the distal nephron by increasing NCC activity, and in each of these cases, SPAK and/or OSR1 seem to be involved. These hormones include aldosterone (56,57), angiotensin II (58,59), insulin (60,61), and vasoressin (62,63). All of these hormones have been shown to increase the abundance of phosphorylated active NCC and, in some cases, have also been shown to increase NCC abundance or stimulate the movement of NCC from intracellular vesicles to the luminal membrane (64–66). Because the WNKs are the only known activators of SPAK and OSR1 in the kidney, these findings strongly suggest that hormones that regulate BP and extracellular fluid volume status recruit WNK-dependent signaling processes to activate NCC through SPAK and OSR1 (Figure 7). Indeed, recent work has shown, for example, that angiotensin II-mediated activation of NCC is a WNK4-dependent process (58). Defining the molecular details of how these physiologically relevant stimuli interface with the WNK-SPAK/OSR1 signaling pathway remains an active area of biomedical research.

Patients who are being treated with the immunosuppressant tacrolimus commonly present with hypertension, hyperkalemia, metabolic acidosis, and hypercalcuria—a clinical picture that in most respects resembles FHHt. Recently, it was shown that tacrolimus stimulates the activity of NCC, likely by enhancing its phosphorylation through the WNK-SPAK/OSR1 pathway (Figure 7) (67). Consistent with this finding, renal transplant patients on tacrolimus exhibited a greater urinary fractional excretion of chloride on bendroflumethiazide, indicating that tacrolimus-associated hypertension and hyperkalemia may be highly sensitive to thiazide diuretics (67). Larger clinical studies are currently underway to determine whether thiazides are superior to other agents as first-line therapy for the treatment of tacrolimus-associated hypertension.

**K⁺ Secretion by the DCT**

After reabsorption of K⁺ along the proximal tubule and loop of Henle, approximately 10% of filtered K⁺ reaches the DCT. As fluid travels down the DCT, the luminal potassium concentration increases, indicating that net K⁺ secretion occurs along the distal tubule. In the early DCT, the rate of K⁺ secretion is low, but it increases significantly in the late DCT (68–70). The enhanced K⁺ secretion parallels the progressive increase in lumen-negative transepithelial voltage observed in the late DCT. Indeed, a substantial component of the increased K⁺ secretion observed in this segment seems to be **voltage-dependent**. Voltage-dependent K⁺ secretion is mediated by the renal outer medullary potassium channel (ROMK; KCNJ1, also known as Kir1.1). ROMK-mediated K⁺ transport is dependent on the driving force for K⁺ secretion, which is primarily determined by electrogenic ENaC-mediated sodium reabsorption (71). Thus, as the activity of ENaC increases in the late DCT, more sodium is reabsorbed, which generates a lumen-negative stimulus for K⁺ efflux through ROMK potassium channels. As one can imagine, enhanced delivery of sodium ions to the late DCT and more downstream ENaC-expressing nephron segments—for example, through the use of loop diuretics—will enhance voltage-dependent K⁺ secretion.

The transepithelial voltage is not the only factor that determines the rate of K⁺ secretion in the DCT. Distal potassium secretion is also **flow-dependent**. Flow-dependent K⁺ secretion is mediated by the “big” or “maxi”-K⁺ channel (BK), a large conductance potassium channel that is expressed in all segments of the distal nephron, including the DCT, CNT, and collecting duct. During states of increased distal tubule flow, shear stress along the DCT activates the channel, possibly by increasing intracellular calcium levels and enhancing intracellular nitric oxide production (72,73). Both of the intracellular signals could increase the BK’s open probability and thereby enhance the rate of K⁺ efflux into the tubular lumen.

These observations have led to an updated model for K⁺ secretion in the distal nephron (Figure 8) (74,75). At baseline conditions, it has been proposed that the primary channel that mediates K⁺ secretion across the DCT lumen is ROMK. Under states of high urinary flow, such as during diuretic use, sodium delivery is enhanced, resulting in increased ENaC-mediated Na⁺ transport, depolarization of the apical membrane, and enhanced voltage-dependent K⁺ secretion through ROMK. In addition, the enhanced rate of urinary flow will trigger intracellular signaling mechanisms that result in enhanced BK activity. Thus, under low-flow conditions, ROMK is active, whereas under high-flow states, both ROMK and BK are active.

Additional K⁺ secretion occurs more distally in the connecting tubule and CCD (71). Classically, the collecting duct has been thought of as the primary nephron segment that mediates K⁺ secretion. This is perhaps owing to the ease with which collecting ducts can be accessed and studied in the laboratory. In contrast to the collecting duct, distal tubules are difficult to isolate and perfuse, and for years this technical problem may have caused physiologists to overlook the importance of the DCT in renal physiology. However, several studies indicate that the late DCT and CNT mediate a substantial fraction of total distal K⁺ secretion (71). Additional studies are needed to...
determine the relative contribution of ROMK and BK in these nephron segments to whole-body potassium homeostasis.

Regulation of Distal Tubule Potassium Transport
Regulation of ROMK Gating

ROMK is an “inward rectifier” potassium channel. This essentially means that the natural tendency of these channels is to transport potassium into cells rather than out of them. However, in the distal tubule, ROMK primarily functions to secrete potassium into the tubular lumen. The reason why ROMK can carry out such a function is because of differences in the chemical and electrical gradients in the DCT, CNT, and CCD. Potassium is the most abundant intracellular cation. Therefore, there is a chemical tendency for potassium to leak outward. Although the voltage on the interior aspect of the luminal membrane is negative, it is not negative enough to counterbalance the high intracellular concentration of positively charged potassium cations. Therefore, K⁺ preferentially flows outward through ROMK. As described above, other channels that move positive charges inward (such as ENaC) will enhance this net outward flow of K⁺.

The capacity of a potassium channel to mediate inward rectification is modulated by a number of intrinsic factors, including the plasma membrane phosphoinositide 2 (76) and polyamines (77), but the most clinically relevant of these regulators of ROMK function is magnesium. Mg²⁺ binds to ROMK at a specific location on its cytoplasmic surface (78–80). By binding to ROMK at this site, Mg²⁺ blocks the channel’s pore from the inside and prevents K⁺ from being secreted. In the absence of adequate intracellular magnesium concentrations, potassium is more freely secreted into the tubular lumen (Figure 9). This phenomenon is currently believed to be an important reason...
why hypomagnesemia is often associated with enhanced distal K$^+$ secretion and refractory hypokalemia (81).

Aldosterone, Hyperkalemia, and Potassium Secretion

Hyperkalemia triggers aldosterone release from the adrenal gland. This results in an elevation of circulating aldosterone levels that enhances mineralocorticoid receptor–dependent signaling processes in the late DCT and downstream nephron segments. The mineralocorticoid receptor then triggers a signaling cascade that ultimately affects ROMK biogenesis. Specifically, the receptor translocates to the nucleus, where it stimulates the transcription of serum- and glucocorticoid-regulated kinase 1 (SGK1). SGK1 then phosphorylates a specific residue located in the cytoplasmic tail of ROMK; this event releases the channel from retention in the endoplasmic reticulum, allowing it to traffic more freely to the apical plasma membrane (82–84). Thus, through direct effects of SGK1 on ROMK traffic, aldosterone seems to ensure that an adequate number of potassium channels are available to facilitate K$^+$ secretion in the distal nephron. In addition to its effects on ROMK traffic, aldosterone also stimulates K$^+$ secretion by activating ENaC (85,86). As discussed above, the effect of this enhanced sodium transport through ENaC generates a lumen-negative transepithelial potential difference, which drives ROMK-mediated K$^+$ secretion (Figure 8).

The renal response to hyperkalemia seems to be much more than simply an aldosterone-dependent phenomenon. Potassium loading induced, for example, by administrating a high K$^+$ diet rapidly increases the number of ROMK channels expressed at the plasma membrane of distal nephron cells within hours of treatment; this effect can be seen before the observed increase in circulating aldosterone levels, suggesting that potassium has a direct effect on cells of the DCT. Similar effects have been noted with other components of the ion transport machinery expressed in the DCT, including the BK channel, the Na$^+$–K$^+$–ATPase, and ENaC (87–89). Recent evidence suggests that the aforementioned WNKs participate in the intracellular response of the DCT to hyperkalemia (90,91), and both WNK1 and WNK4 have been shown by several groups to influence the plasma membrane trafficking of both ROMK and BK channels in vitro (92–94). In fact, the bulk of evidence strongly suggests that the WNK signaling pathway seems to regulate transcellular sodium and potassium transport through completely different mechanisms, and it is this differential regulation of the two pathways that leads to the coexistence of hypertension and hyperkalemia seen in patients with FHHt (95). Although exciting progress has been made in this regard, additional studies are needed to define the in vivo relevance of these pathways to whole-body BP and potassium homeostasis in the general population.

Divalent Cation Reabsorption in the DCT

Although less is known about calcium and magnesium handling in the distal tubule, recent discoveries in the molecular mechanisms regulating these processes have expanded our understanding of how the DCT contributes to divalent cation homeostasis.

Calcium

Approximately 7%–10% of filtered calcium is reabsorbed in the DCT. In contrast to other segments of the nephron, which passively reabsorb calcium through paracellular routes, 100% of the calcium that is reabsorbed in the
DCT occurs by active transcellular mechanisms. Apical calcium transport is mediated by the transient receptor potential channel subfamily V member 5 (TRPV5) (96) (Figure 10). On entry, Ca^{2+} associates with the calcium binding protein calbindin-D28K, which helps to buffer intracellular calcium levels and keep free calcium concentrations low (97) (Figure 10). After calcium is shuttled by calbindin-D28K to the basolateral surface, Ca^{2+} is extruded into the peritubular fluid by a calcium ATPase and the Type 1 sodium calcium exchanger (NCX1; Figure 10).

Of these transport processes, apical calcium entry through TRPV5 seems to be the rate-limiting step for calcium reabsorption, and the activity of TRPV5 is regulated by...
Hypercalcemia is a common side effect of thiazide diuretics. Apical calcium reabsorption in the DCT (Figure 11). Thiazide-associated hyper-reabsorption of calcium with sodium and water in hypocalciuria, which is probably because of the passive transport characteristics allow it to effectively function as a magnesium channel. Mutations in TRPM6 cause hypomagnesemia with secondary hypocalcemia, a rare Mendelian disorder of renal magnesium wasting.

Other than this fairly recently described magnesium transport pathway, relatively little is known about other transport processes that facilitate transcellular Mg$^{2+}$ reabsorption. Unlike its fellow divalent cation calcium, evidence does not exist for an intracellular magnesium binding protein that buffers cytosolic magnesium concentrations. With regards to basolateral Mg$^{2+}$ transport, a mechanism exists for the reclamation of magnesium back into the peritubular fluid and bloodstream; however, the precise molecular identities of these transport processes remain obscure. One putative candidate is cyclin M2 (ancient conserved domain-containing protein 2), a distal nephron-expressed basolateral membrane protein that has been described by some as an Mg$^{2+}$/metal ion transporter (107) and others as a magnesium sensor (108,109). Another candidate is the basolateral magnesium transporter SLC41A1, which is localized to the DCT. A loss-of-function mutation in this gene was recently shown to cause nephronophthisis, suggesting that it plays an important role in tubular function and morphology (110).

Emerging evidence gained from studies of families with rare inherited disorders of magnesium wasting suggests that the membrane voltage of the DCT plays a critical role in the control of magnesium reabsorption. In isolated dominant hypomagnesemia, mutations in the small $\gamma$-subunit of the Na$^+$/K$^+$/ATPase, FXDY2, alter pump function (111-113). Specifically, the absence of this subunit, which is highly expressed in the thick ascending limb of Henle’s loop and DCT, has been shown to alter the affinity of the Na$^+$/K$^+$/ATPase for sodium and potassium (114,115). FXDY2 mutations reduce subunit binding to the pump, although it is still unclear how this reduced interaction causes hypomagnesemia. The aforementioned EAST/SeSAME syndrome (Figure 3) is another hypomagnesemic disorder, in which the basolateral membrane voltage is likely altered. In this case, inactivating mutations of Kir4.1 reduce K$^+$ recycling across the basolateral membrane, which could result in reduced sodium pump function, alteration of the basolateral membrane potential, and diminished transcellular magnesium transport (26).

In 2009, a fascinating new Mendelian disorder was discovered, in which patients develop hypomagnesemia because of a presumed alteration in the apical membrane voltage of the DCT. This autosomal dominant form of hypomagnesemia was attributed to a mutation in the Shaker-related voltage-gated K$^+$ channel Kv1.1 (116). This channel is exclusively expressed at the apical membrane of
the early and late DCTs and secretes K$^+$ into the tubular lumen. It is believed that by secreting K$^+$, Kv1.1 channels extrude positive charges into the lumen that provide a driving force for TRPM6-dependent Mg$^{2+}$ transport (Figure 12). Mutation of Kv1.1 at a specific residue renders the channel nonfunctional, and one mutant allele is sufficient to cause the disease, presumably because of dominant negative inhibition of the remaining wild-type allele (117). A current theory is that the lack of functional Kv1.1 channels decreases the efflux of potassium cations into the lumen, which, in turn, would be expected to make the intracellular voltage on the luminal membrane more positive, decreasing the voltage gradient for luminal Mg$^{2+}$ entry. Although this hypothesis is provocative, the pathophysiology may not be so simple: as discussed above in the section on ROMK gating, such a change in the luminal membrane potential would be expected to markedly enhance ROMK-mediated K$^+$ secretion and cause hypokalemia, which is not observed in the disorder. Perhaps compensatory changes in ROMK, BK, or even ENaC expression in more downstream nephron segments, where Kv1.1 is not expressed (such as the CNT and CCD) (116), mitigate potassium losses, although to date, this hypothesis has not been tested.

EGF has emerged as an important regulator of Mg$^{2+}$ handling in the DCT. In a Dutch family with a recessive form of selective hypomagnesemia, affected members had a mutation in the gene encoding the precursor form of EGF (118). This precursor molecule, pro-EGF, is a membrane protein that is expressed at the basolateral membrane of DCT cells. On arrival, the pro-EGF can be proteolytically cleaved to release soluble EGF, which then can interact with the EGF receptor and trigger a signaling cascade that stimulates TRPM6 (Figure 12). The hypomagnesemia-causing mutation results in missorting of pro-EGF, such that its delivery to the basolateral membrane of the DCT cells is inefficient. Ultimately, this impairs EGF-dependent signaling processes, including EGF-mediated stimulation of TRPM6 (119). The clinical importance of EGF-dependent regulation of TRPM6 is illustrated by the side effect profile of cetuximab, an EGF receptor antagonist used to treat colonic adenocarcinomas. Patients receiving systemic cetuximab can develop profound renal magnesium wasting because of the
inhibition of EGF-dependent stimulation of TRPM6 in the DCT.

Hypomagnesemia is a common side effect of thiazide diuretics. Thiazides sharply downregulate TRPM6 expression in the DCT (105), causing decreased magnesium reabsorption and hypomagnesemia. The mechanism by which TRPM6 expression is downregulated by thiazides remains unknown, although several mechanisms have been proposed (105). One attractive hypothesis is that thiazide-induced hypoplasia of DCT cells decreases TRPM6 protein abundance, reducing the total number of channels expressed at the luminal membrane.

Summary

The DCT is a short but critically important nephron segment. The DCT consists of two distinct subsegments; both subsegments are highly metabolically active and play key roles in sodium, potassium, and divalent cation homeostasis. Insights from genetic diseases of BP, potassium, and calcium and magnesium balance have expanded our knowledge of the molecular machinery that mediates these processes. Although it is already known that the DCT plays an important part in certain common pathophysiological states, such as diuretic resistance, the role of the DCT in many other clinically relevant disease states awaits additional investigation. Now that our understanding of the regulatory machinery of the DCT is more complete, such investigations can be pursued with the intent of understanding disease pathogenesis and developing new strategies for the treatment of DCT-related disorders, such as hypertensive and/or edematous states, hyper- or hypokalemic tubulopathies, disorders of divalent ion balance, and nephrolithiasis.

Acknowledgments

This work was supported, in part, by the National Institutes of Health Grants R01-DK51496 (to D.H.E.), R01-DK095841 (to D.H.E.), and P30-DK079307 (to the Pittsburgh Center for Kidney Research), R01-DK088145 (to A.R.S.), and a Mid-Level Veterans Affairs Career Development Grant (to A.R.S.).

Disclosures

None.

References

53. Vitari AC, Deak M, Morrice NA, Alessi DR: The WNK1 and
55. Vidal-Petiot E, Elvira-Matelot E, Mutig K, Soukaseum C, Baudrie
causes human hypertension.
Uchida S: Impaired KLHL3-mediated ubiquitination of WNK4
diverts the thiazide-sensitive NaCl cotransporter to the lyso-
membrane.
Macartney TJ, Wood NT, Alessi DR, Kurz T: The CUL3-KLHL3
interacts with and ubiquitylates WNK isoforms: Disease-
like 3 and Cullin 3 regulate electrolyte homeostasis via
vacuolar H+, K+-ATPase (hV-ATPase) and WNK4 protein kinases that are mutated in Gordon's hyperten-
sion syndrome phosphorylate and activate SPAK and OSR1
serves agonist function in the lymphatic system to
abolished inactivation of ROMK channels by angiotensin II, db-cAMP or acetylcholine.

**Distal Convoluted Tubule, Subramanya et al. 2014**

Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML,
Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW,
Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML,
Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW,
Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML,
Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW,
Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML,
Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW,
Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML,
Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW,
Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML,
Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW,
Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML,
Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW,
Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML,
Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW,
Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML,
Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW,
Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML,
Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW,
Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML,
Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW,
Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML,
Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW,
Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML,
Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW,
Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML,
Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW,
Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML,
Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW,
Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML,
Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW,
Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML,
Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW,
Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML,
Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW,
Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML,
Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW,
Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML,
Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW,
Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML,
Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW,
Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML,
Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW,
Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML,
Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW,
Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML,
Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW,
Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML,
Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW,
Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML,
Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW,
Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML,
Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW,
Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML,
Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW,
Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML,
Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW,
Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML,
Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW,
Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML,
Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW,
Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML,
Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW,
Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML,
Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW,
Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML,
Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW,
Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML,
Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW,
2162 Clinical Journal of the American Society of Nephrology


Published online ahead of print. Publication date available at www.cjasn.org.